Eli Lilly and Company » Facts at a Glance

Skip to: Major Marketed Products, Employees, Financials, Research and Development, Staff, Cost of New Pharmaceuticals, Awards & Recognition

A heritage more than 130 years strong: company founded on May 10, 1876
Headquarters located in Indianapolis, Indiana, U.S.A.
38,080 employees worldwide (as of December 31, 2011).
Approximately 7,306 employees engaged in research and development
Clinical research conducted in more than 50 countries
Research and development facilities located in 8 countries
Manufacturing plants located in 13 countries
Products marketed in 125 countries

Major Marketed Products

(Dates indicate the year of first global launch. For complete prescribing information, please visit product website)

2011	BYDUREON® (exenatide 2 mg powder and solvent for prolonged release suspension for injection), the first and only once-weekly glucagon-like peptide (GLP-1) receptor agonist, for the treatment of type 2 diabetes. (EU) (in collaboration with Amylin Pharmaceuticals, Inc. and Alkermes, Inc.)
2011	TRADJENTA™ (linagliptin) tablets for the treatment of type 2 diabetes (in collaboration with Boehringer Ingelheim Pharmaceuticals, Inc.)
2011	Axiron® (testosterone) topical solution CIII for replacement therapy in males for conditions associated with the deficiency or absence of endogenous testosterone.
2010	Livalo® (pitavastatin)is indicated for adults as an adjunctive therapy to diet for the treatment of primary hyperlipidemia or mixed dyslipidemia.(in collaboration with Kowa Pharmaceuticals America, Inc.)
2009	Adcirca™ (tadalafil) for pulmonary arterial hypertension (Canada) (EU) (U.S.) (outlicensed for US sales and marketing to United Therapeutics) (Japan) (marketed and sold by Nippon Shinyaku)
2009	Efient™ (prasugrel) for the prevention of atherothrombotic events in patients with ACS undergoing percutaneous coronary intervention (Europe)(in collaboration with Daiichi Sankyo Company, Ltd.) Effient™ (prasugrel) for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndromes who to be managed with an artery-opening procedure known as percutaneous coronary intervention (PCI). (U.S.)(in collaboration with Daiichi Sankyo, Inc.)
2005	BYETTA® (exenatide) for type 2 diabetes (in collaboration with Amylin Pharmaceuticals, Inc.)
2004	Alimta® (pemetrexed) for malignant pleural mesothelioma for second-line treatment of non-squamous non-small-cell lung cancer (NSCLC) (2004) for first-line treatment of non-squamous NSCLC (2008) for the maintenance treatment of non-squamous (NSCLC) (2009)
2004	Cymbalta® (duloxetine)for treatment of major depressive disorder, established in four short term-trials (2004) and one maintenance trial (2007) for management of neuropathic pain (DPNP) associated with diabetic peripheral neuropathy (2004) for treatment of generalized anxiety disorder, established in three short-term trials (2007) and one maintenance trial (2009) for management of fibromyalgia (2008) for management of chronic musculoskeletal pain, established in studies in patients with chronic low back pain and chronic pain due to osteoarthritis (2010) (in collaboration with Quintiles Transnational Corp. in the U.S. and with Shionogi & Co. Ltd. in Japan)
2004	Erbitux® (cetuximab) for later-stage EGFR-expressing metastatic colorectal cancer for locally or regionally advanced squamous cell head and neck cancer (2006) for later-stage recurrent or metastatic squamous cell head and neck cancer (2006) (in collaboration with Bristol-Myers Squibb Co. in North America and Japan, and Merck KGaA outside of North America and in Japan)
2004	Symbyax® (olanzapine/fluoxetine) for bipolar depression for acute treatment of adult patients with major depressive disorder who have not responded to two separate trials of different antidepressants of adequate dose and duration in their current episode (2009)
2004	Yentreve® (duloxetine) for stress urinary incontinence (outside the U.S.)
2003	Cialis® (tadalafil) for erectile dysfunction for once daily use (2007)
2003	Strattera® (atomoxetine) for attention-deficit hyperactivity disorder (ADHD) in children, adolescents, and adults for maintenance treatment of ADHD in children and adolescents (2008)
2002	Forteo® (teriparatide) for treatment of men and postmenopausal women with osteoporosis who are at high risk for a fracture for the treatment of glucocorticoid-induced osteoporosis (2008; Europe)
1998	Evista® (raloxifene) for prevention of osteoporosis in postmenopausal women for treatment of osteoporosis in postmenopausal women (1999) for reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis (2007) for reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer (2007) (in collaboration with Chugai Pharmaceutical Co., Ltd. in Japan)
1996	Zyprexa® (olanzapine) for schizophrenia for acute bipolar mania (2000) Zyprexa® Zydis® tablet (2000) for schizophrenia maintenance (2001) as combination therapy with lithium or valproate for acute bipolar mania (2002) for bipolar maintenance (2003) Rapid-acting IntraMuscular formulation (2004) Zyprexa® granules (2004; launched in Japan only) Zypadhera™ for maintenance treatment of adult patients with schizophrenia sufficiently stabilized during acute treatment with oral olanzapine (2009)
1996	Humalog® (lispro recombinant insulin) for treatment of type 1 and type 2 diabetes Humalog® Mix 75/25 (1999) Humalog® Mix 50/50 (1999)
1995	Gemzar® (gemcitabine) for first-line non-small cell lung cancer for pancreatic cancer (1996) for bladder cancer (1999; outside the U.S.) for metastatic breast cancer (2003) for recurrent ovarian cancer (2004) for biliary tract cancer (2006; Japan)
1987	Humatrope® (somatropin recombinant) for growth failure caused by pediatric growth hormone deficiency for replacement therapy for adult growth hormone deficiency (1995) for short stature caused by Turner syndrome (1997) for idiopathic short stature (2003)
1983	Humulin® (human insulin recombinant) for type 1 and type 2 diabetes

Employees (as of 6/30/11) Indianapolis : 10,167
Indiana (excluding Indianapolis) : 904
U.S. (excluding Indiana) : 6,338
Outside U.S. : 20,657
Worldwide total : 38,066

Financials - 2010

(dollars in millions, except per-share data)

Net sales: $23,076.0
Net income as reported: $5,069.5
Earnings per share as reported: $4.58
Dividends paid per share: $1.96

Research and Development

2010 Expenditures

$4,884 million/year
$407 million/month
$94 million/week
$19 million/workday

Increase from previous year: 13 percent
R&D as a percentage of sales: 21 percent

StaffEmployees engaged in Lilly R&D activities: 7,306
Percent of total work force: 19 percent

Cost of New Pharmaceuticals

Average cost to discover and develop a new drug: $800 million to $1.2 billion
Average length of time from discovery to patient: 10 to 15 years

Awards & RecognitionReceiving recognition for a job well done is always a special honor. It's an affirmation that we are sustaining Lilly's heritage of service and commitment to helping others. Making a difference in people's lives is often reward enough. Nevertheless, at Lilly we are proud of the awards we have received for the accomplishments and contributions we've made in our industry and to society overall.

The Scientist Magazine "Top 30 Best Places to Work in Industry"
Fortune Magazine "Global Top Companies for Leaders"
Points of Light Institute “Award of Excellence Corporate Engagement”
U.S. Department of the Interior “Take Pride in America”
United Way Spirit of America® Award
Forbes.com “Most Generous U.S. Companies”
Human Rights Campaign Foundation “Corporate Equity Index – 100 Ranking”
Institutional Investor “Top Shareholder-Friendly Companies”
Med Ad News “Most Admired Global Companies”
Science magazine “Best Companies for Scientists”
U.S. Small Business Administration “Outstanding Rating for Supplier Diversity Initiatives”
United Way of America “Summit Award for Corporate Philanthropy, Community Investment and Community Impact”
Working Mother Magazine “100 Best Companies for Working Mothers”